Many pharmaceutical companies this week trotted out fresh price increases on existing products, a common mid-year occurrence that has not abated despite the Trump administration’s assertions that prices are coming down.

Why it matters: As we’ve reported over and over again, the pharmaceutical industry’s practices have not changed one iota even with the administration’s pricing blueprint, and drug companies still have every incentive to raise prices.

• Pfizer raised list prices on more than 100 drugs as of July 1, David Crow of the Financial Times scooped.
• Seattle Genetics and Sanofi also instituted mid-year hikes on some products, Meg Tirrell of CNBC reported.
• Several other companies followed suit with large and small increases, others in the industry tell Axios.

Go deeper: The drug pricing war that leaves patients caught in the middle